Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy.
about
Treatment of multiple myeloma bone disease: experimental and clinical data.Utilizing BMP-2 muteins for treatment of multiple myelomaMultiple myeloma in the marrow: pathogenesis and treatments.Management of bone disease in multiple myeloma.Myeloma and Bone Disease.Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma.Molecular mechanisms, current management and next generation therapy in myeloma bone disease.A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.Emerging treatment approaches for myeloma-related bone disease.Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease.Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.Pathogenesis of bone disease in multiple myeloma: from bench to bedside.Bone-Targeted Therapies in Cancer-Induced Bone Disease.Bone Disease in Multiple Myeloma.Lenalidomide consolidation treatment in patients with multiple myeloma suppresses myelopoieses but spares erythropoiesis.
P2860
Q30868833-42A4E193-1421-47A2-A6B8-F28FE34E4158Q36367921-79A74300-574E-41AD-BE2B-77D1B00D8234Q36725401-2A311889-B5FB-4491-9820-EDD308ACAC5FQ38179039-D55F0DED-5123-44B4-8DE0-71B6560ECAF6Q38598342-19F310A7-3980-4565-865C-B7E0542B8ABFQ38685897-44F37043-52FD-43F9-8EFD-D59A64D6665DQ38749233-FAA0F0FC-1B24-45C1-8998-C6218A1C95F4Q39024879-1FEE154D-EEE9-4A5E-9803-2ABB34A0D052Q39090721-B5CF2280-6B3B-4091-89BD-02CF3419D9EFQ40111192-9CFB2D2E-928C-45C1-8514-2449D5B7D898Q41963512-708780EB-65E4-47F6-A968-F5712BB77089Q47734632-F528054B-348A-45CE-9C61-C918DF79A365Q48110513-D1166881-1D28-492B-88B5-A08056C9FB1AQ50888455-17E49EA9-D3E9-445A-8F6C-1E9D66D50E59Q51656403-A5560ABD-EAD8-41FE-9F44-444EF4AC03E6
P2860
Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Lenalidomide in combination wi ...... a novel anti-myeloma strategy.
@en
Lenalidomide in combination wi ...... a novel anti-myeloma strategy.
@nl
type
label
Lenalidomide in combination wi ...... a novel anti-myeloma strategy.
@en
Lenalidomide in combination wi ...... a novel anti-myeloma strategy.
@nl
prefLabel
Lenalidomide in combination wi ...... a novel anti-myeloma strategy.
@en
Lenalidomide in combination wi ...... a novel anti-myeloma strategy.
@nl
P2093
P356
P1433
P1476
Lenalidomide in combination wi ...... a novel anti-myeloma strategy.
@en
P2093
A Mahindra
M Fulciniti
P2888
P304
P356
10.1038/LEU.2013.50
P577
2013-02-18T00:00:00Z
P5875
P6179
1039228373